Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Other Non-Current Assets: 2015-2024

Historic Other Non-Current Assets for Seres Therapeutics (MCRB) over the last 8 years, with Dec 2024 value amounting to $8.7 million.

  • Seres Therapeutics' Other Non-Current Assets fell 12.21% to $8.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.7 million, marking a year-over-year decrease of 12.21%. This contributed to the annual value of $8.7 million for FY2024, which is 86.33% down from last year.
  • Latest data reveals that Seres Therapeutics reported Other Non-Current Assets of $8.7 million as of FY2024, which was down 86.33% from $63.4 million recorded in FY2023.
  • Seres Therapeutics' 5-year Other Non-Current Assets high stood at $63.4 million for FY2023, and its period low was $8.0 million during FY2021.
  • Over the past 3 years, Seres Therapeutics' median Other Non-Current Assets value was $10.5 million (recorded in 2022), while the average stood at $27.5 million.
  • Per our database at Business Quant, Seres Therapeutics' Other Non-Current Assets skyrocketed by 505.70% in 2023 and then plummeted by 86.33% in 2024.
  • Seres Therapeutics' Other Non-Current Assets (Yearly) stood at $8.0 million in 2021, then spiked by 30.81% to $10.5 million in 2022, then soared by 505.70% to $63.4 million in 2023, then crashed by 86.33% to $8.7 million in 2024.